AI Article Synopsis
- Endometrial cancer (EC) is the sixth most common cancer in women globally, with about 20% of patients facing a poor prognosis despite advances in early-stage detection.
- Research highlights the role of non-coding RNAs (like lncRNAs, microRNAs, and circRNAs) in the development and progression of EC, which could lead to new therapeutic targets.
- The review discusses how these ncRNAs interact with the Wnt/β-catenin signaling pathway, suggesting that understanding this relationship may improve treatment strategies for EC.
Article Abstract
Endometrial cancer (EC) ranks as the sixth most common malignancy in women around the world. Although low‑grade and early‑stage EC commonly have an excellent prognosis, ~20% of EC patients experience an unfavorable prognosis. Identifying the pathogenesis and novel therapeutic targets may help address this group of patients. Non‑coding (nc)RNAs, such as long non‑coding RNAs (lncRNAs), microRNAs and circular RNAs (circRNAs), have been associated with EC occurrence and development. In addition, the aberrant activation of the Wnt/β‑catenin signaling pathway can promote the proliferation, invasion, migration and epithelial‑to‑mesenchymal transition (EMT) of EC cells. The network of ncRNAs has also been demonstrated to inhibit or activate the Wnt/β‑catenin signaling pathway. In the present review, ncRNAs, the Wnt/β‑catenin signaling pathway, and their crosstalk in EC were summarized and highlighted. This information is expected to provide novel insights into improving the management of EC using RNA as therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308485 | PMC |
| http://dx.doi.org/10.3892/mmr.2023.13037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!